Chronic Hepatitis C
Early viral disappearance predicts sustained response in hepatitis C patients
Published in Hepatitis Weekly, January 31st, 2005
According to published research from Japan, "data on 334 patients with hepatitis C virus (HCV) genotype 1b and high viral levels were extracted from two multicenter double-blind studies conducted in Japan comparing interferon (IFN) alpha-2b plus ribavirin (n=209) with IFN alpha-2b alone (n=125) for 24 weeks."
"HCV RNA assay was conducted before and 4, 12, and 24 weeks after the start and 4, 12, and 24 weeks after the end of treatment. Both sustained viral response (SVR) rate and relapse rate after the end of treatment were analyzed in relation to baseline viral levels and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-01-31)
More Articles from Hepatitis Weekly
- Cancer Therapy
Viral eradication augments non-resective liver cancer therapy - Diagnostics
Anti-hepatitis A virus IgG avidity assay distinguishes viral reactivation - Diagnostics
Researchers detail new studies and findings in the area of diagnostics - Diagnostics
Researchers report details of new studies and findings in the area of diagnostics - Diagnostics
Target-capture polymerase chain reaction measures hepatitis B load accurately - Immunology
Researchers detail new studies and findings in the area of immunology - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
